13.07.2015 Views

UK BIOBANK Ethics and Governance Framework ... - Wellcome Trust

UK BIOBANK Ethics and Governance Framework ... - Wellcome Trust

UK BIOBANK Ethics and Governance Framework ... - Wellcome Trust

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

of a person with dementia to continue to participate in Biobank the Bill may allow them to withdrawthat person. The holder of an PA [power of attorney] would also be able to withdraw a person fromBiobank.’ [O]58. This respondent also noted that the words <strong>and</strong> sentiments of incapacitated people must berespected when tests are being carried out, as discussed below:‘We would also urge <strong>UK</strong> Biobank to include a clause in its guidance that states if a person who haslost capacity appears to object to any test or procedure, by words or actions, this should be taken as arequest to withdraw from participation.’ [O]3.3.8 Expectation of personal financial gain59. The majority of respondents found the EGF’s proposals around the expectation ofpersonal financial gain ‘very acceptable’ or ‘acceptable’ (n=14, 74%). Respondentsargued that it was important to outline to participants, from the outset, that there would beno financial or material gain from their involvement in <strong>UK</strong> Biobank.‘In relation to the statement in the framework document "participants will not be offered anysignificant financial or material inducement to participate. . ." In our view it should be made clear thatparticipants will not be offered any financial or material inducement "significant" or otherwise.’ [O]60. One respondent felt that people were unlikely to get involved purely out of altruisticfeelings <strong>and</strong> that other rewards or benefits needed to be considered:‘Money <strong>and</strong> healthcare information might not be the right solution but other measures can be used forthem to feel special.’ [P]3.4 Confidentiality61. This section explores respondents’ comments <strong>and</strong> concerns about the EGF’s treatment ofconfidentiality in relation to its:• commitment to maintaining confidentiality;• treatment of anonymisation;• policy on re-identification of samples <strong>and</strong> data.62. Most respondents thought the <strong>Framework</strong>’s treatment of confidentiality was ‘veryacceptable’ or ‘acceptable’ (commitment to maintaining confidentiality: n = 15 [83%],treatment of anonymisation: n = 13 [72%], policy on re-identification: n = 13 [72%]).63. A number of respondents commented that the proposed system, although not “foolproof”or fully outlined to date, was sound in principle:‘In general, these principles are acceptable. They will never be foolproof, as if someone in a 'sensitive'position is determined to abuse the system, they will be able to. However, this is probably as effective asystem as it can be.’ [O]‘The steps that have been taken to ensure this seem to strike a balance between protecting the interestsof participants <strong>and</strong> ensuring that the data actually are available for scientific analysis.’ [O]24

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!